Maria Rosaria Galdiero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6265335/publications.pdf

Version: 2024-02-01

72 papers 7,050 citations

36 h-index 95266 68 g-index

72 all docs 72 docs citations

72 times ranked

12126 citing authors

#	Article	IF	CITATIONS
1	Gender dimorphism in IgA subclasses in T2-high asthma. Clinical and Experimental Medicine, 2023, 23, 929-941.	3.6	5
2	Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Seminars in Cancer Biology, 2022, 79, 180-196.	9.6	64
3	Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Seminars in Cancer Biology, 2022, 79, 203-216.	9.6	12
4	Neutrophil extracellular traps in cancer. Seminars in Cancer Biology, 2022, 79, 91-104.	9.6	75
5	Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments. European Heart Journal, 2022, 43, 330-332.	2.2	6
6	Neutrophil extracellular traps and neutrophil-derived mediators as possible biomarkers in bronchial asthma. Clinical and Experimental Medicine, 2022, 22, 285-300.	3.6	28
7	Neutrophil Extracellular Traps, Angiogenesis and Cancer. Biomedicines, 2022, 10, 431.	3.2	39
8	Impact of a cardioâ€oncology unit on prevention of cardiovascular events in cancer patients. ESC Heart Failure, 2022, 9, 1666-1676.	3.1	9
9	Size-based effects of anthropogenic ultrafine particles on activation of human lung macrophages. Environment International, 2022, 166, 107395.	10.0	9
10	LPS-mediated neutrophil VEGF-A release is modulated by cannabinoid receptor activation. Journal of Leukocyte Biology, 2021, 109, 621-631.	3.3	25
11	Macrophage-polarizing stimuli differentially modulate the inflammatory profile induced by the secreted phospholipase A2 group IA in human lung macrophages. Cytokine, 2021, 138, 155378.	3.2	13
12	IL-33 and Superantigenic Activation of Human Lung Mast Cells Induce the Release of Angiogenic and Lymphangiogenic Factors. Cells, 2021, 10, 145.	4.1	33
13	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. Current Oncology Reports, 2021, 23, 13.	4.0	38
14	Vascular endothelial growth factors and angiopoietins as new players in mastocytosis. Clinical and Experimental Medicine, 2021, 21, 415-427.	3.6	12
15	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. Expert Opinion on Drug Safety, 2021, 20, 1-10.	2.4	8
16	The Interplay between the Immune and the Endocannabinoid Systems in Cancer. Cells, 2021, 10, 1282.	4.1	31
17	Roles of Immune Cells in Hereditary Angioedema. Clinical Reviews in Allergy and Immunology, 2021, 60, 369-382.	6.5	9
18	Orofacial granulomatosis: Clinical and therapeutic features in an Italian cohort and review of the literature. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2189-2200.	5.7	8

#	Article	IF	Citations
19	Human Lung-Resident Macrophages Express and Are Targets of Thymic Stromal Lymphopoietin in the Tumor Microenvironment. Cells, 2021, 10, 2012.	4.1	22
20	Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. Expert Opinion on Investigational Drugs, 2021, 30, 913-921.	4.1	3
21	Hereditary angioedema attack: what happens to vasoactive mediators?. International Immunopharmacology, 2020, 78, 106079.	3.8	7
22	New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101370.	4.7	60
23	VEGF-A in Cardiomyocytes and Heart Diseases. International Journal of Molecular Sciences, 2020, 21, 5294.	4.1	121
24	Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmunity Reviews, 2020, 19, 102590.	5.8	37
25	Anaplastic Thyroid Cancer Cells Induce the Release of Mitochondrial Extracellular DNA Traps by Viable Neutrophils. Journal of Immunology, 2020, 204, 1362-1372.	0.8	45
26	First Report of De Novo Nivolumab-Induced Oligoarthritis in a Young Man With Relapsing Classic Hodgkin Lymphoma. Journal of Clinical Rheumatology, 2020, Publish Ahead of Print, .	0.9	2
27	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. International Journal of Molecular Sciences, 2019, 20, 3934.	4.1	69
28	Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors. Cell, 2019, 178, 346-360.e24.	28.9	176
29	Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis. Journal of Immunology Research, 2019, 2019, 1-14.	2.2	8
30	Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. International Journal of Molecular Sciences, 2019, 20, 4413.	4.1	140
31	Physiological Roles of Mast Cells: Collegium Internationale Allergologicum Update 2019. International Archives of Allergy and Immunology, 2019, 179, 247-261.	2.1	75
32	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 2019, 20, 2560.	4.1	72
33	Immunosuppressive therapy with rituximab in common variable immunodeficiency. Clinical and Molecular Allergy, 2019, 17, 9.	1.8	36
34	Mast Cells in Early Rheumatoid Arthritis. International Journal of Molecular Sciences, 2019, 20, 2040.	4.1	24
35	Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease. International Journal of Molecular Sciences, 2019, 20, 834.	4.1	48
36	Prostaglandin D ₂ receptor antagonists in allergic disorders: safety, efficacy, and future perspectives. Expert Opinion on Investigational Drugs, 2019, 28, 73-84.	4.1	50

#	Article	IF	Citations
37	Roles of neutrophils in cancer growth and progression. Journal of Leukocyte Biology, 2018, 103, 457-464.	3.3	113
38	Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1765-1767.	2.8	49
39	Eosinophils: The unsung heroes in cancer?. Oncolmmunology, 2018, 7, e1393134.	4.6	184
40	Cancer Inflammation and Cytokines. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028662.	5.5	175
41	Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. Lancet Oncology, The, 2018, 19, 1545-1546.	10.7	16
42	The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. Frontiers in Immunology, 2018, 9, 2601.	4.8	74
43	Secreted Phospholipases A2 in Hereditary Angioedema With C1-Inhibitor Deficiency. Frontiers in Immunology, 2018, 9, 1721.	4.8	19
44	Innate effector cells in angiogenesis and lymphangiogenesis. Current Opinion in Immunology, 2018, 53, 152-160.	5 . 5	92
45	Potential involvement of neutrophils in human thyroid cancer. PLoS ONE, 2018, 13, e0199740.	2.5	54
46	Neutrophils Involvement in Human Thyroid Cancer. Journal of Allergy and Clinical Immunology, 2018, 141, AB122.	2.9	0
47	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry, 2018, 25, 1327-1339.	2.4	99
48	Lipopolysaccharide-Elicited TSLPR Expression Enriches a Functionally Discrete Subset of Human CD14+CD1c+ Monocytes. Journal of Immunology, 2017, 198, 3426-3435.	0.8	26
49	Cardiac Toxicity of Immune Checkpoint Inhibitors. Circulation, 2017, 136, 1989-1992.	1.6	83
50	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	4.5	186
51	Controversial role of mast cells in skin cancers. Experimental Dermatology, 2017, 26, 11-17.	2.9	69
52	GM-CSF and IL-3 Modulate Human Monocyte TNF-α Production and Renewal in In Vitro Models of Trained Immunity. Frontiers in Immunology, 2017, 7, 680.	4.8	38
53	Are Mast Cells MASTers in Cancer?. Frontiers in Immunology, 2017, 8, 424.	4.8	243
54	Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic and Antiangiogenic Factors by Human Neutrophils. Frontiers in Immunology, 2017, 8, 443.	4.8	65

#	Article	IF	CITATIONS
55	Bidirectional Mast Cell–Eosinophil Interactions in Inflammatory Disorders and Cancer. Frontiers in Medicine, 2017, 4, 103.	2.6	88
56	Abstract SY06-01: Tumor-associated myelomonocytic cells as therapeutic targets. , 2017, , .		0
57	Occurrence and significance of tumorâ€associated neutrophils in patients with colorectal cancer. International Journal of Cancer, 2016, 139, 446-456.	5.1	141
58	Are Basophils and Mast Cells Masters in HIV Infection?. International Archives of Allergy and Immunology, 2016, 171, 158-165.	2.1	24
59	The immune network in thyroid cancer. Oncolmmunology, 2016, 5, e1168556.	4.6	88
60	PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer. Cell, 2015, 160, 700-714.	28.9	334
61	Phagocytes as Corrupted Policemen in Cancer-Related Inflammation. Advances in Cancer Research, 2015, 128, 141-171.	5.0	81
62	Immune mediators as potential diagnostic tools for colorectal cancer: from experimental rationale to early clinical evidence. Expert Review of Molecular Diagnostics, 2014, 14, 387-399.	3.1	6
63	Polarized Activation of Macrophages. , 2014, , 37-57.		3
64	Tumor-associated Macrophages in Cancer Growth and Progression. , 2013, , 451-471.		1
65	Macrophage plasticity and polarization in tissue repair and remodelling. Journal of Pathology, 2013, 229, 176-185.	4.5	1,868
66	Tumor associated macrophages and neutrophils in tumor progression. Journal of Cellular Physiology, 2013, 228, 1404-1412.	4.1	346
67	Neutrophils in innate and adaptive immunity. Seminars in Immunopathology, 2013, 35, 377-394.	6.1	221
68	Tumor associated macrophages and neutrophils in cancer. Immunobiology, 2013, 218, 1402-1410.	1.9	500
69	Angiogenesis, Lymphangiogenesis and Atopic Dermatitis. Chemical Immunology and Allergy, 2012, 96, 50-60.	1.7	33
70	Mast cells have a protumorigenic role in human thyroid cancer. Oncogene, 2010, 29, 6203-6215.	5.9	190
71	Human Cardiac Mast Cells in Anaphylaxis. Chemical Immunology and Allergy, 2010, 95, 98-109.	1.7	36
72	Role of the RNA-Binding Protein Tristetraprolin in Glucocorticoid-Mediated Gene Regulation. Journal of Immunology, 2008, 180, 8342-8353.	0.8	86